Total Payments
$111,290
2024 Payments
$2,997
Companies
45
Transactions
258
Medicare Patients
6,455
Medicare Billing
$1.4M
Payment Breakdown by Category
Consulting$51,578 (46.3%)
Other$46,137 (41.5%)
Travel$7,185 (6.5%)
Food & Beverage$6,240 (5.6%)
Education$149.85 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $51,578 | 29 | 46.3% |
| Honoraria | $46,137 | 40 | 41.5% |
| Travel and Lodging | $7,185 | 16 | 6.5% |
| Food and Beverage | $6,240 | 148 | 5.6% |
| Education | $149.85 | 7 | 0.1% |
| Unspecified | $0 | 18 | 0.0% |
Payments by Type
General
$111,290
240 transactions
Ownership
$0
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $51,865 | 66 | $0 (2024) |
| Daiichi Sankyo Inc. | $38,435 | 41 | $0 (2024) |
| Astellas Pharma US Inc | $5,854 | 2 | $0 (2023) |
| Heron Therapeutics, Inc. | $4,143 | 6 | $0 (2018) |
| Gilead Sciences, Inc. | $4,133 | 7 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $2,286 | 9 | $0 (2023) |
| Deciphera Pharmaceuticals Inc. | $800.00 | 2 | $0 (2021) |
| Athenex Pharmaceutical Division, LLC | $600.00 | 2 | $0 (2020) |
| Foundation Medicine, Inc. | $351.42 | 2 | $0 (2019) |
| Janssen Biotech, Inc. | $282.04 | 7 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,997 | 53 | Cornerstone Specialty Network LLC ($1,950) |
| 2023 | $27,572 | 67 | Cornerstone Specialty Network LLC ($23,997) |
| 2022 | $19,243 | 55 | Daiichi Sankyo Inc. ($11,772) |
| 2021 | $21,094 | 19 | Cornerstone Specialty Network LLC ($9,581) |
| 2020 | $21,799 | 19 | Daiichi Sankyo Inc. ($18,904) |
| 2019 | $4,327 | 12 | Cornerstone Specialty Network LLC ($3,779) |
| 2018 | $5,836 | 14 | Cornerstone Specialty Network LLC ($3,282) |
| 2017 | $8,423 | 19 | Gilead Sciences Inc ($4,097) |
All Payment Transactions
258 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | Genentech USA, Inc. | Gazyva (Biological), Itovebi, Tecentriq | Food and Beverage | In-kind items and services | $21.97 | General |
| Category: BioOncology | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.70 | General |
| Category: Oncology | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Education | In-kind items and services | $25.95 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $18.40 | General |
| 11/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $24.01 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $26.69 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $23.46 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/08/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: ONCOLOGY | ||||||
| 10/05/2024 | Medtronic, Inc. | SYNCHROMEDII (Device) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: Drug Infusion Systems | ||||||
| 09/17/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: Oncology | ||||||
| 08/28/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.20 | General |
| Category: ONCOLOGY | ||||||
| 08/27/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.40 | General |
| Category: ONCOLOGY | ||||||
| 08/27/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: Oncology | ||||||
| 08/26/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.91 | General |
| Category: Oncology | ||||||
| 08/13/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: Oncology | ||||||
| 08/12/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $23.77 | General |
| Category: Oncology | ||||||
| 08/05/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $25.80 | General |
| Category: HORMONE THERAPY | ||||||
| 07/23/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: ONCOLOGY | ||||||
| 07/22/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $20.52 | General |
| Category: ONCOLOGY | ||||||
| 07/09/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.04 | General |
| Category: Oncology | ||||||
| 07/09/2024 | Genentech USA, Inc. | Perjeta (Biological), Phesgo | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: BioOncology | ||||||
| 07/01/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $17.14 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 1,109 | 9,923 | $475,729 | $208,688 |
| 2022 | 33 | 1,395 | 17,277 | $583,909 | $239,918 |
| 2021 | 41 | 2,091 | 22,077 | $1.4M | $504,403 |
| 2020 | 40 | 1,860 | 12,137 | $1.1M | $411,953 |
Total Patients
6,455
Total Services
61,414
Medicare Billing
$1.4M
Procedure Codes
142
All Medicare Procedures & Services
142 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 16 | 6,480 | $213,840 | $120,059 | 56.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 172 | 354 | $65,136 | $31,013 | 47.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 36 | 123 | $43,050 | $11,840 | 27.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 59 | 79 | $19,592 | $10,589 | 54.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 91 | 131 | $16,375 | $7,667 | 46.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 143 | 397 | $23,026 | $4,109 | 17.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 184 | 536 | $18,760 | $4,049 | 21.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 32 | 185 | $14,060 | $3,980 | 28.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 48 | 213 | $9,372 | $2,215 | 23.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 12 | 17 | $4,216 | $1,800 | 42.7% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 13 | 104 | $4,472 | $1,760 | 39.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $4,248 | $1,703 | 40.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 31 | 35 | $4,900 | $1,570 | 32.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 13 | 14 | $2,576 | $1,009 | 39.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 13 | 33 | $5,973 | $798.37 | 13.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 12 | 37 | $3,330 | $756.01 | 22.7% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 30 | 49 | $2,744 | $654.64 | 23.9% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 13 | 27 | $3,105 | $652.86 | 21.0% |
| 84165 | Protein measurement, serum | Office | 2023 | 15 | 56 | $3,360 | $589.68 | 17.5% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 13 | 40 | $1,600 | $364.40 | 22.8% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 19 | 20 | $1,240 | $295.60 | 23.8% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 24 | 49 | $1,470 | $290.08 | 19.7% |
| 83550 | Iron binding capacity | Office | 2023 | 22 | 32 | $1,056 | $274.24 | 26.0% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 11 | 16 | $1,216 | $263.36 | 21.7% |
| 83540 | Iron level | Office | 2023 | 22 | 32 | $800.00 | $202.88 | 25.4% |
About Dr. Gregory Litton, M.D
Dr. Gregory Litton, M.D is a Medical Oncology healthcare provider based in Murray, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487603916.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Litton, M.D has received a total of $111,290 in payments from pharmaceutical and medical device companies, with $2,997 received in 2024. These payments were reported across 258 transactions from 45 companies. The most common payment nature is "Consulting Fee" ($51,578).
As a Medicare-enrolled provider, Litton has provided services to 6,455 Medicare beneficiaries, totaling 61,414 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 142 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Murray, UT
- Active Since 05/10/2006
- Last Updated 10/10/2016
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1487603916
Products in Payments
- Enhertu (Drug) $22,905
- ENHERTU (Drug) $10,362
- XTANDI (Drug) $5,852
- SUSTOL (Drug) $4,143
- Zydelig (Drug) $4,097
- Imbruvica (Drug) $2,240
- QINLOCK (Drug) $800.00
- Oral Paclitaxel (Drug) $600.00
- FOUNDATIONACT (Device) $300.00
- LIBTAYO (Biological) $178.60
- DARZALEX (Biological) $160.01
- OPDIVO (Biological) $140.56
- IMBRUVICA (Drug) $140.35
- ZEJULA (Drug) $128.50
- GILOTRIF (Drug) $124.75
- Lonsurf (Drug) $115.37
- ORGOVYX (Drug) $77.98
- VERZENIO (Drug) $76.35
- NINLARO (Drug) $68.73
- Zoladex (Drug) $67.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.